Clinical Trial

Effect of Dexmedetomidine on Acute Kidney Injury After Ascending Aortic Surgeries

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Acute kidney injury (AKI) is a frequent and serious complication after ascending aortic surgeries requiring cardiopulmonary bypass (CPB). Dexmedetomidine, a selective α-2 adrenoreceptor agonist, may reduce AKI because of its sympatholytic and anti-inflammatory effects against ischaemia reperfusion injury. We investigate the effect of dexmedetomidine administration on AKI after ascending aortic surgeries requiring CPB in a placebo-controlled randomised controlled trial.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-26; most recent amendment 2026-06-07.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-06-07
Trial Details
NCT Number NCT06958367
Lead Sponsor Ain Shams University
Conditions Aki After Ascending Aortic Surgeries
Enrollment 78 participants
Start Date 2025-11-01
Primary Completion 2026-11-02 (estimated)
Study Completion 2026-11-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-09